

# INFECTION CONTROL<sup>AND</sup>

## HOSPITAL EPIDEMIOLOGY

Volume 11, Number 10 • October 1990

### EDITORIAL

- Surveillance of the Surgical Wound** 513  
Ronald Lee Nichols, MD

### ORIGINAL ARTICLES

- Comprehensive Surveillance of Surgical Wound Infections in Outpatient and Inpatient Surgery** 515

Farrin A. Manian, MD, MPH;  
Lynn Meyer, RN, MPH, CIC

- Variation in Risk for Falls by Clinical Department: Implications for Prevention** 521

Judith M. Rohde, MSN; Ann H. Myers, ScD;  
David Vlahov, PhD

- Persistence of Antibody in Healthcare Workers Vaccinated Against Hepatitis B** 525

Alan C. Street, MB, BS; Teresa Z. Weddle, MPH;  
Wayne R. Thomann, DrPH;  
Ellen W. Lundberg, BS; George W. Jackson, MD;  
John D. Hamilton, MD

- Plasmid DNA Fingerprinting of *Acinetobacter calcoaceticus* Subspecies *anitratus* From Intubated and Mechanically Ventilated Patients** 531

Alan I. Hartstein, MD; Virginia H. Morthland, BS;  
J. William Rourke, Jr., MS; Joan Freeman, RN;  
Susan Garber, RN; Renee Sykes, BS;  
Abdel L. Rashad, MD, PhD

### TOPICS IN CLINICAL MICROBIOLOGY

- Achromobacter xylosoxidans Bacteremia** 539  
Kathleen A. McGann, MD; Mary Provencher, MT;  
Cindy Hoegg, RN; George H. Talbot, MD

### READERS' FORUM

- Group A Streptococcal Bacteremias Associated With Intravascular Catheters** 542

Michael A. Martin, MD; Joan N. Hebden, RN;  
Carlos I. Bustamante, MD; Lewis J. Rubin, MD

### LETTERS TO THE EDITOR

- Chickenpox in Apparently 'Immune' Hospital Workers** 510

Inge Gurevich, RN, MA; Linda Jensen, MT;  
Robert Kalter, MD; Burke A. Cunha, MD

### BOOK REVIEWS

- Clinical Immunology Principles and Laboratory Diagnosis*** 550

Catherine Sheehan  
Reviewed by Charles T. Lutz, MD, PhD

- Nosocomial infections: New Issues and Strategies for Prevention*** 550

David J. Weber, MD; William A. Rutala, PhD, eds.  
Reviewed by Graham Ayliffe, MD, FRCPath

- SHEA NEWSLETTER** 545

---

The Official Journal of The Society of Hospital Epidemiologists of America

From SmithKline Biologicals



## Hepatitis B Vaccine (Recombinant)

### Choice of dosing regimens

**Alternate 0, 1, 2 month dosing regimen for certain populations\***

20 mcg recombinant dose

**Helps to ensure immune response in adult patients of all ages**

	Engerix-B®	Recombivax HB®†
Adult dose (mcg)	20	10
Standard dosing regimen (0, 1 and 6 months)	✓	✓
Alternate 0, 1, 2 month dosing regimen for certain populations*	✓	
Published efficacy data: Neonates born of infected mothers'	✓	✓
VACTRAC™—computer software for vaccination tracking and compliance	✓	
Bar-coded, unit-dose vials	✓	
Lowest cost per dose <sup>2</sup>	✓	

\*For those recently exposed to the virus (including needlestick exposure), certain travelers to high-risk areas and neonates born of infected mothers. When prolonged maintenance of protective antibody titers is desired, a booster dose at month 12 is recommended.

**Lowest Cost Per Dose<sup>2</sup>**


**Extensively tested and well tolerated<sup>4</sup>**

**State-of-the-art recombinant technology**

**14 million doses distributed in over 87 countries<sup>3</sup>**

**Switch to Engerix-B<sup>®</sup>**

**Can be used to complete a course of vaccination  
initiated with another hepatitis B vaccine<sup>3,4</sup>**



<sup>1</sup>Hepatitis B Vaccine (Recombinant), MSD.  
<sup>2</sup>Please see brief summary of prescribing information on adjacent page for a complete listing of adverse reactions, contraindications, warnings and precautions.

©SmithKline Beecham, 1990.

# Engerix-B®

## Hepatitis B Vaccine (Recombinant)

See complete prescribing information in SK&F literature or PDR. The following is a brief summary.

**INDICATIONS AND USAGE:** Engerix-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. Immunization is recommended in persons of all ages, especially those who are, or will be at increased risk of exposure to hepatitis B virus.

**CONTRAINDICATIONS:** Hypersensitivity to yeast or any other component of the vaccine is a contraindication for use of the vaccine.

**WARNINGS:** Do not give additional injections to patients experiencing hypersensitivity after an Engerix-B injection. (See CONTRAINDICATIONS.)

Hepatitis B has a long incubation period. Hepatitis B vaccination may not prevent hepatitis B infection in individuals who had an unrecognized hepatitis B infection at the time of vaccine administration. Additionally, it may not prevent infection in individuals who do not achieve protective antibody titers.

**PRECAUTIONS: General:** As with any percutaneous vaccine, keep epinephrine available for use in case of anaphylaxis or anaphylactoid reaction.

As with any vaccine, delay administration, if possible, in persons with any febrile illness or active infection.

**Pregnancy:** Pregnancy Category C. Animal reproduction studies have not been conducted with Engerix-B. It is also not known whether Engerix-B can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Give Engerix-B to a pregnant woman only if clearly needed.

**Nursing Mothers:** It is not known whether Engerix-B is excreted in human milk. Because many drugs are excreted in human milk, use caution when giving Engerix-B to a nursing woman.

**Pediatric Use:** Engerix-B has been shown to be well tolerated and highly immunogenic in infants and children of all ages. Newborns also respond well; maternally transferred antibodies do not interfere with the active immune response to the vaccine.

**ADVERSE REACTIONS:** Engerix-B is generally well tolerated. During clinical studies involving over 10,000 individuals distributed over all age groups, no serious adverse reactions attributable to vaccine administration were reported. As with any vaccine, however, it is possible that expanded commercial use of the vaccine could reveal rare adverse reactions not observed in clinical studies.

Ten double-blind studies involving 2,252 subjects showed no significant difference in the frequency or severity of adverse experiences between Engerix-B and plasma-derived vaccines. In 36 clinical studies, a total of 13,495 doses of Engerix-B were administered to 5,071 healthy adults and children who were initially seronegative for hepatitis B markers, and healthy neonates. All subjects were monitored for 4 days post-administration. Frequency of adverse experiences tended to decrease with successive doses of Engerix-B. Using a symptom checklist,\* the most frequently reported adverse reactions were injection site soreness (22%), and fatigue\* (14%). Other reactions are listed below.

**Incidence 1% to 10% of injections:** Induration; erythema; swelling; fever (> 37.5°C); headache; dizziness.\*

\*Parent or guardian completed forms for children and neonates. Neonatal checklist did not include headache, fatigue or dizziness.

**Incidence < 1% of injections:** P a m : pruritus; ecchymosis; sweating; malaise; chills; weakness; flushing; tingling; hypotension; influenza-like symptoms; upper respiratory tract illnesses; nausea; anorexia; abdominal pain/cramps; vomiting; constipation; diarrhea; lymphadenopathy; pain/stiffness in arm, shoulder or neck; arthralgia; myalgia; back pain; rash; urticaria; petechiae; erythema; somnolence; insomnia; irritability; agitation.

Additional adverse experiences have been reported with the commercial use of Engerix-B outside the United States. Those listed below are to serve as alerting information to physicians: Anaphylaxis; erythema multiforme including Stevens-Johnson syndrome; angioedema; arthritis; tachycardia/palpitations; bronchospasm including asthma-like symptoms; abnormal liver function tests; rigiraine; syncope; paresis; neuropathy including hypoesthesia, paresthesia, Guain-Barré syndrome and Bell's palsy; transverse myelitis; thrombocytopenia; eczema; purpura; herpes zoster; vertigo; conjunctivitis; keratitis; visual disturbances.

**Potential Adverse Experiences:** In addition, certain other adverse experiences not observed with Engerix-B have been reported with Heptavax-B† and/or Recombivax HB‡. † Those listed below are to serve as alerting information to physicians: Optic neuritis.

**HOW SUPPLIED:** 20 mcg/mL in Single-Dose Vials in packages of 1, 10 and 25 vials.

NOC 0007-3860-01 (package of 1)  
NOC 0007-3860-11 (package of 10)  
NOC 0007-3860-16 (package of 25)

10 mcg/0.5 mL in Single-Dose Vials in packages of 1 vial  
NOC 0007-3859-01 (package of 1)

† plasma-derived, Hepatitis B Vaccine, MSD  
‡ yeast-derived, Hepatitis B Vaccine, MSD.

Manufactured by **SmithKline Biologicals**, Rixensart, Belgium  
Distributed by **Smith Kline & French Laboratories**  
Division of SmithKline Beckman Corp., Philadelphia, PA 19101

Date of issuance Aug. 1989

BRS-EB:L6

Engerix-B is a registered trademark of SmithKline Beecham

#### References:


1. Poovorawan Y, Sanpavat S, Pongpunlert W, et al: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. *JAMA* 1989; 261(22):3278-3281.
2. Based on *Medi-Span*® Hospital Formulary Pricing Guide, December 1989.
3. Data on file, SK&F.
4. Bush L, Moonsammy G, Boscia J: Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. *Hepatology* 1989; 10:689.


## HATS OFF TO FIRST CLASS SERVICE


At SLACK Incorporated we believe our subscribers are first class people. That's why we do everything possible to publish first class journals. And, that's why we maintain a TOLL-FREE CUSTOMER SERVICE HOTLINE. For the first class customer service you deserve, call:


1-800-257-8290


Talk to a SLACK Customer Service Representative about:

 **Subscriptions.** Subscribing by phone is quick and easy; it only takes a minute and Visa and Mastercard are accepted.

 **Renewals.** Early subscription renewal helps avoid possible interruptions in service.

 **Change of Address.** Please notify us four weeks in advance to assure prompt delivery to your new address.

 **Questions or Problems.** Delivery problems or questions about your subscriptions can be handled instantly.



# SLACK

6900 Grove Road,  
Thorofare, NJ 08086

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

<b>EDITORIAL</b>	<b>Surveillance of the Surgical Wound</b> Ronald Lee Nichols, MD	513
<b>ORIGINAL ARTICLES</b>	<b>Comprehensive Surveillance of Surgical Wound Infections in Outpatient and Inpatient Surgery</b> Farrin A. Manian, MD, MPH; Lynn Meyer, RN, MPH, CIC	515
	<b>Variation in Risk for Falls by Clinical Department: Implications for Prevention</b> Judith M. Rohde, MSN; Ann H. Myers, ScD; David Vlahov, PhD	521
	<b>Persistence of Antibody in Healthcare Workers Vaccinated Against Hepatitis B</b> Alan C. Street, MB, BS; Teresa Z. Weddle, MPH; Wayne R. Thomann, DrPH; Ellen W. Lundberg, BS; George W. Jackson, MD; John D. Hamilton, MD	525
	<b>Plasmid DNA Fingerprinting of <i>Acinetobacter calcoaceticus</i> Subspecies <i>anitratus</i> From Intubated and Mechanically Ventilated Patients</b> Alan I. Hartstein, MD; Virginia H. Morthland, BS; J. William Rourke, Jr., MS; Joan Freeman, RN; Susan Garber, RN; Renee Sykes, BS; Abdel L. Rashad, MD, PhD	531
<b>SPECIAL SECTIONS</b>	<b>Topics in Clinical Microbiology</b> <i>Achromobacter xylosoxidans</i> <b>Bacteremia</b> Kathleen A. McGann, MD; Mary Provencher, MT; Cindy Hoegg, RN; George H. Talbot, MD	539
	<b>Readers' Forum</b> <b>Group A Streptococcal Bacteremias Associated With Intravascular Catheters</b> Michael A. Martin, MD; Joan N. Hebden, RN; Carlos I. Bustamante, MD; Lewis J. Rubin, MD	542
<b>DEPARTMENTS</b>	<b>Letters to the Editor</b>	510
	<b>Information for Authors</b>	549
	<b>SHEA Newsletter</b>	545
	<b>Book Reviews</b>	550
	<b>Calendar of Events</b>	548
	<b>Classified Marketplace</b>	552

**The ideas and opinions expressed by contributing authors do not necessarily reflect those of the editors or publisher.**

**Publisher:** Infection Control and Hospital Epidemiology (ISSN-0899-823X) is published monthly by SLACK Incorporated, 6900 Grove Road Thorofare New Jersey 08086 Telephone (609) 848-1000

**Copyright 1990:** All rights reserved No part of this publication may be reproduced without written permission from the publisher

**Subscriptions:** Requests should be addressed to the publisher (except Japan) In Japan contact Woodbell Incorporated 4-22-11 Kitakasai, Edogawaku Tokyo 134, Japan Subscription rates in the US and possessions Individual One year-\$60 00 Two years-\$95 00, Three years-\$125.00 Institutional One year-\$70 00, Two years-\$110 00, Three years-\$150 00, Canada \$16 00 additional each year all other countries \$30 00 additional each year Single copies of current issues may be obtained for \$8 00 United States and possessions, \$16 00 all other countries

**F&prints:** All requests to reprint or use material published herein should be addressed to Lester J Robeson, SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086 For reprint orders and prices, contact Fran Micaletti at (609) 848-1000 Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1 00 per copy, plus 5 15 per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem MA 01970 This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes or for creating new collective works

**Change of address:** Notice should be sent to the publisher six weeks in advance of effective date Include old and new addresses with zip codes The publisher cannot accept responsibility for undelivered copies Second-class postage is paid at Thorofare, New Jersey 08086, and additional entry points Postmaster: Send address changes to SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08066

As of Volume 1, Number 1, INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in *Index Medicus*, *Current Contents—Clinical Practice Hospital Literature Index*, *Cumulative Index to Nursing and Allied Health Literature*, and *Nursing Abstracts*

**EDITORIAL OFFICES**

Vanderbilt University School of Medicine  
 A-1131 Medical Center North  
 Nashville, TN 37232-2637  
 (615) 343-1095; (615) 343-1882 (FAX)  
 Email: iche@mcmail.vanderbilt.edu

**EDITOR**

Michael D. Decker, MD, MPH

**MANAGING EDITOR**

Susan Cantrell

**STATISTICAL EDITOR**

Beverly G. Mellen, PhD

**SENIOR ASSOCIATE EDITORS**

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

**ASSOCIATE EDITORS**

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

**SECTION EDITORS****Beyond Infection Control:****The New Hospital Epidemiology**

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

**Disinfection and Sterilization**

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

**Emerging Infectious Diseases**

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

**From the Laboratory**

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

**Information Management**

John A. Sellick, DO

Buffalo, New York

**The International Perspective**

Mary D. Nettleman, MD, MS

Richmond, Virginia

**Issues in Surgery**

James T. Lee, MD, PhD

St. Paul, Minnesota

**Medical News**

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

**Practical Healthcare Epidemiology**

Loreen A. Herwaldt, MD

Iowa City, Iowa

**SHEA News**

Murray D. Batt, MD

Clarksburg, West Virginia

**Statistics for Hospital Epidemiology**

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

**Topics in Long-Term Care**

Philip W. Smith, MD

Omaha, Nebraska

**Topics in Occupational Medicine**

David Weber, MD, MPH

Chapel Hill, North Carolina

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY<sup>®</sup>

**EDITORIAL ADVISORY BOARD**

- Jacques F. Acar, MD Paris, France  
 J. Wesley Alexander, MD Cincinnati, Ohio  
 Paul Arnow, MD Chicago, Illinois  
 Graham A.J. Ayliffe, MD Birmingham, United Kingdom  
 Neil L. Barg, MD Yakima, Washington  
 Elizabeth Ann Bolyard, RN, MPH, CIC Atlanta, Georgia  
 John M. Boyce, MD Providence, Rhode Island  
 Professor Dr. Ilja Braveny Munich, Federal Republic of Germany  
 Charles Bryan, MD Columbia, South Carolina  
 Christian Brun-Buisson, MD Creteil, France  
 Donald E. Craven, MD Boston, Massachusetts  
 Sue Crow, MSN, RN, CIC Shreveport, Louisiana  
 Franz Daschner, MD Freiburg, Federal Republic of Germany  
 Leigh G. Donowitz, MD Charlottesville, Virginia  
 Charles E. Edmiston, Jr., PhD Milwaukee, Wisconsin  
 Theodore C. Eickhoff, MD Denver, Colorado  
 Bruce Farber, MD Manhasset, New York  
 Victoria J. Fraser, MD St. Louis, Missouri  
 Peter C. Fuchs, MD, PhD Black Butte, Oregon  
 Richard A. Garibaldi, MD Farmington, Connecticut  
 Velvl Greene, PhD, MPH Beer Sheva, Israel  
 Robert Gaynes, MD Atlanta, Georgia  
 David W. Gregory, MD Nashville, Tennessee  
 David K. Henderson, MD Bethesda, Maryland  
 Peter N.R. Heseltine, MD Los Angeles, California  
 Karen Hoffmann, RN, CIC, MS Chapel Hill, North Carolina  
 Marguerite McMillan Jackson, RN, PhD San Diego, California  
 Janine Jagger, MPH, PhD Charlottesville, Virginia  
 William R. Jarvis, MD Atlanta, Georgia  
 Douglas S. Kernodle, MD Nashville, Tennessee  
 Robert H. Latham, MD Nashville, Tennessee  
 Lewis B. Lefkowitz, MD Nashville, Tennessee  
 Hsieh-Shong Leu, MD, MSc Taipei, Taiwan  
 Jack Levy, MD Brussels, Belgium  
 Victor Lorian, MD Bronx, New York  
 Dennis G. Maki, MD Madison, Wisconsin  
 Professor Dr. Walter Marget Munich, Federal Republic of Germany  
 William J. Martone, MD Bethesda, Maryland  
 Allison McGeer, MD Toronto, Ontario, Canada  
 John E. McGowan, Jr., MD Atlanta, Georgia  
 Jonathan L. Meakins, MD, DSc Montreal, Quebec, Canada  
 Raf Mertens, MD Brussels, Belgium  
 Robert R. Muder, MD Pittsburgh, Pennsylvania  
 Joseph M. Mylotte, MD, CIC Buffalo, New York  
 Lindsay Nicolle, MD Winnipeg, Manitoba, Canada  
 Juhani Ojajarvi, MD Helsinki, Finland  
 Michael T. Osterholm, PhD, MPH Minneapolis, Minnesota  
 Jan Evans Patterson, MD San Antonio, Texas  
 Sindy M. Paul, MD Trenton, New Jersey  
 Michael A. Pfaller, MD Iowa City, Iowa  
 Samuel Ponce de Leon, MD, MSc Mexico City, Mexico  
 Isaam Raad, MD Houston, Texas  
 Manfred L. Rotter, MD, DipBact Vienna, Austria  
 Theodore Sacks, MD Jerusalem, Israel  
 William E. Scheckler, MD Madison, Wisconsin  
 Kent Sepkowitz, MD New York City, New York  
 Denis Spelman, MD Prahran Victoria, Australia  
 Michael L. Tapper, MD New York, New York  
 Clyde Thornsberry, PhD Brentwood, Tennessee  
 Professor Leonid P. Titov Minsk, Republic of Belarus  
 Timothy R. Townsend, MD Millwood, Virginia  
 Antoni Trilla, MD, PhD Barcelona, Spain  
 Professor Wang Shu-Qun Beijing, People's Republic of China  
 J. John Weems, Jr., MD Greenville, South Carolina  
 Robert A. Weinstein, MD Chicago, Illinois  
 Professor Dr. W. Weuffen Greifswald, Federal Republic of Germany  
 Sergio B. Wey, MD São Paulo, Brazil  
 Rebecca Wurtz, MD Evanston, Illinois

**SLACK Incorporated**

6900 Grove Road  
 Thorofare, New Jersey 08086  
 (609) 848-1000

**Vice President/Group Publisher**

Richard N. Roash

**Publisher**

John C. Carter

**Editorial Director**

Jennifer Kilpatrick

**Production Editor**

Shirley P. Strunk, ELS

**Assistant Editor**

Eileen C. Anderer

**Circulation Manager**

Lester J. Robeson, CCCC

**Production Director**

Christine Malin

**Production Coordinator**

Joanne Patterson

**Publishing Director/ Advertising**

Wayne McCourt

**Pharmaceutical Group Sales Director**

Michael LoPresti

**Advertising Sales Representative**

Jennine Kane

**Classified/Recruitment Sales Manager**

Michele Burch

**DISPOSA-CUF™**  
**CRITIKON**  
a Johnson & Johnson company

# The Single-Patient Inflation System.

Make it part of your infection control team.

Critikon's DISPOSA-CUF™ Complete Inflation System can help assure compliance with your infection control procedures. It has been specifically designed for single-patient use. The entire assembly—bulb, valve and cuff—are disposed of at the end of the patient stay. The hassle and time associated with disinfecting reusable inflation systems is eliminated. So is any possibility of cross-contamination.

The DISPOSE-CUF Inflation System features a bladderless blood pressure cuff that is durable enough to last during the patient's stay. It's sized to fit the patient's arm comfortably and securely. And it's priced to be cost-effective.

Call your Critikon dealer today for more information.



**CRITIKON**

a Johnson & Johnson company

Critikon, Inc., 4110 George Rd., P.O. Box 31800,  
Tampa, FL 33631-3800  
1-800-237-2033 (FL: 1-800-282-4151)